Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for high-risk adults with mild COVID-19 (Phase 2b)
2020-005395-35Phase 2Unknown
- Sponsor
- Gates Medical Research Institute
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Rivaroxaban (Xarelto) with Control (standard of care) (2 arms). Primary endpoint: Progression to moderate or severe COVID-19. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005395-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005395-35.